MedPath

A drug-drug interactions and food-effect study of S-600918 in healthy adult participants

Phase 1
Conditions
Refractory chronic cough
Registration Number
JPRN-jRCT2031200413
Lead Sponsor
agata Tsutae
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Male
Target Recruitment
42
Inclusion Criteria

Apparently healthy as determined by the investigator or subinvestigator based on medical assessment.
-Weight within the range 50 kg (inclusive) to 85 kg (exclusive), and body mass index (BMI) within the range 18.5 kg/m2 (inclusive) to 25.0 kg/m2 (inclusive).
-Capable of giving the signed ICF as described in this protocol which includes compliance with the requirements and deadlines listed in the ICF and in this protocol.

Exclusion Criteria

-History or presence of significantly disorders that, in the opinion of the investigator or subinvestigator, would constitute a safety concern or donfound data interaption.
-Exposure to more than 4 study drugs within 12 months prior to the first dose of study intervention.
-Previous administration of S-600918.
-Ineligibility for the study as considered by the investigator or subinvestigator.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Maximum plasma concentration (Cmax), time to maximum plasma concentration (Tmax), area under the concentration-time curve (AUC), terminal elimination half-life (t1/2,z), and terminal elimination rate constant (lambdaz), mean residence time (MRT), apparent total clearance (CL/F), and apparent volume of distribution in the terminal elimination phase (Vz/F)
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath